Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA by Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Patrick Lefebvre, Steven R. Feldman

Connect to this object online.

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States by Lisa Harding, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Cindy Chen, Dominic Pilon

Connect to this object online.

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia by Dee Lin, Dominic Pilon, Laura Morrison, Aditi Shah, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela Benson

Connect to this object online.

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA by Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. Feldman

Connect to this object online.

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States by Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman

Connect to this object online.

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors by Jessica A. Walsh, Iris Lin, Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Emond, Louise H. Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D. Chakravarty, Philip Mease

Connect to this object online.